CDE seeks comments on technical guidance for pharmaceutical research and evaluation of gene transduction and modification systems
On September 30, 2020, the Center for Drug Evaluation (CDE) of the National Medical Products Administration began soliciting opinions on its official website regarding pharmaceutical research and evaluation techniques related to gene drugs. The full text is as follows:
Notice on publicly soliciting opinions on the Technical Guideline for Pharmaceutical Research and Evaluation of Gene Transduction and Modification Systems (Draft for Comment)
Release date: 20200930. To standardize the pharmaceutical research of gene transduction and modification systems for cell therapy products, unify evaluation standards, and guide the research and application of related products, our Center, based on drawing on relevant domestic and international regulatory standards and through preliminary research, document drafting, expert consultation and departmental discussion, has formed the Technical Guideline for Pharmaceutical Research and Evaluation of Gene Transduction and Modification Systems (Draft for Comment). We now solicit public opinions through the Center's website (www.cde.org.cn), and welcome valuable opinions and suggestions from all sectors.
If you have any opinions or suggestions for further improvement or supplementation, please fill in the specific information in the comment feedback form and provide feedback to us by email. Thank you for your participation and support! Contacts: Lu Jiaqi, Wei Wei. Email: lujq@cde.org.cn; weiw@cde.org.cn. The deadline for soliciting opinions: October 30, 2020.
Center for Drug Evaluation, National Medical Products Administration. September 30, 2020.
The CDE website also attached three original documents with the notice: Attachment 1: Technical Guideline for Pharmaceutical Research and Evaluation of Gene Transduction and Modification Systems (Draft for Comment).pdf; Attachment 2: Drafting Notes of the Technical Guideline for Pharmaceutical Research and Evaluation of Gene Transduction and Modification Systems (Draft for Comment).pdf; Attachment 3: Comment Feedback Form for the Technical Guideline for Pharmaceutical Research and Evaluation of Gene Transduction and Modification Systems (Draft for Comment).docx.
According to the requirements of the main text of the comment solicitation, this guideline provides advisory technical requirements for gene transduction and modification systems, aiming to provide guidance for the R&D and application of drug registration applicants (hereinafter referred to as applicants), and also serves as an important reference for regulators in supervising and evaluating gene transduction and modification systems used in the production of cell therapy products. For gene-modified cell therapy products registered as drugs, the gene transduction and modification systems used in their production, as key materials, are subject to the supervision of the National Medical Products Administration (NMPA). In R&D and application, while following this guideline, the relevant laws and regulations such as the Drug Administration Law of the People's Republic of China, the Measures for the Administration of Drug Registration and the Pharmacopoeia of the People's Republic of China shall also be complied with, and other relevant guidelines and subsequently issued regulations in this field shall be comprehensively referenced. The applicability to specific issues should be analyzed on a case-by-case basis.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.